Sequence Bio, a biotechnology company researching the founder effect in Newfoundland and Labrador to accelerate novel drug target discovery, is pleased to announce that it was selected to present two research posters at the American Society of Human Genetics’ (ASHG) 2023 meeting, the largest human genetics and genomics meeting and exposition in the world.
In their posters, members of Sequence Bio’s Research and Data Science team shared insights from the company’s flagship genetic research study in Newfoundland and Labrador, the NL Genome Project:
Sequence Bio’s posters were presented in person at ASHG 2023, held November 1-5, 2023, in Washington, DC.
The ASHG Annual Meeting, produced by the American Society of Human Genetics (ASHG), is the largest human genetics and genomics meeting and exposition in the world. Held in October, it provides a forum for the presentation and discussion of cutting-edge science in all areas of human genetics. Highlights include invited symposia; abstract-driven plenary, platform, and poster sessions; education/trainee workshops; and career opportunities and networking events.
For more information, please visit ASHG.org
VP, Market Development